Article Information
History
- July 1, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Brian A Ference, MD, MPhil, MSc1,*,
- Thatcher B. Ference1,
- Alberico L Catapano, PhD2,
- Stephen J. Nicholls, MBBS, PhD3 and
- Kausik K Ray, MD, MPhil4
- 1DeepCausalAI Institute for Clinical Translation, Cambridge, U.K.
- 2Department of Pharmacological and Biomolecular Sciences, University of Milan and Multimedica IRCCS, Milano, Italy
- 3Victorian Heart Institute, Monash University, Melbourne, Australia
- 4Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London U.K
- ↵*Correspondence to: Professor Brian A Ference, MD, MPhil, MSc, FACC, FESC DeepCausalAI Institute for Clinical Translation, Cambridge, UK, baference{at}DeepCausalAI.org
Posted July 01, 2024.
A NATUrally Randomized trial Evaluating a vaccine-like strategy to lower LDL by inhibiting PCSK9 on the lifetime risk of major cardiovascular events (NATURE-PCSK9)
